# Evaluation of the Efficacy and Safety of ALV003 in Symptomatic in Celiac Disease Patients

> **NCT01917630** · PHASE2 · UNKNOWN · sponsor: **Alvine Pharmaceuticals Inc.** · enrollment: 500 (estimated)

## Conditions studied

- Celiac Disease

## Interventions

- **DRUG:** ALV003
- **DRUG:** placebo

## Key facts

- **NCT ID:** NCT01917630
- **Lead sponsor:** Alvine Pharmaceuticals Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2013-08
- **Primary completion:** 2015-04
- **Final completion:** 2015-06
- **Target enrollment:** 500 (ESTIMATED)
- **Last updated:** 2014-12-17


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01917630

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01917630, "Evaluation of the Efficacy and Safety of ALV003 in Symptomatic in Celiac Disease Patients". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT01917630. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*